Hot Biotechs (fka HOTBIO)

[sarals]

Hi muelhead,

I was looking for a biotech board on IHub and here it is and here you are again : )

I have a couple favorites, but my top performer for the last 12 months was on GNTA (84% according to my quicken data). So here's a little DD on Genta:

Summary
----------------
Genta, Inc. is a biopharmaceutical company with a diversified product portfolio that is focused on anticancer therapy. Genta's research platform is anchored by four key components: Antisense Technology; Androgenics Products; Gallium Products and Decoy Aptamers. The products from each of these platforms address significant unmet medical needs. The Company's lead antisense compound, Genasense, is in late-stage clinical trials for treatment of melanoma, multiple myeloma and chronic lymphocytic leukemia. Other current studies with Genasense target acute myeloid leukemia and cancers of the prostate, lung, colon and breast. Genasense is being used to enhance the activity of other standard types of anticancer therapy. The drug has received both Fast Track and Orphan Drug designation from the United States Food and Drug Administration.

Recent News on Genasense(TM)
----------------------------
"BERKELEY HEIGHTS, N.J., May 14 /PRNewswire/ -- Genta Incorporated (Nasdaq: GNTA - news) announced the presentation of new clinical findings that showed a high level of antitumor activity when Genasense(TM), the Company's lead antisense compound, was used in combination for the treatment of prostate cancer. The results were presented Saturday at the annual meeting of the American Society of Clinical Oncology in San Francisco, CA."

Whole article:
http://biz.yahoo.com/prnews/010514/nym018.html

Most recent news about Genta
-------------------------------------
Tuesday June 5, 2001 09:00 AM
Company Press Release
SOURCE:Genta Incorporated

Genta to Present at Wall Street Analyst Forum

BERKELEY HEIGHTS, N.J., June 5 /PRNewswire/ -- Genta Incorporated (Nasdaq: GNTA) announced today that it will present at The Wall Street Analyst Forum's Institutional Investor Conference in New York City on Wednesday, June 6th, 2001 at 11:50 AM Eastern time. Approximately 80 public companies will be presenting at the Conference from June 4th, 2001 through June 7th, 2001. Mr. Thomas Burger, Genta's Vice President of Business Development will provide conference attendees with a comprehensive summary of Genta's late stage development programs.

Investors may access an Internet webcast of the presentation at: http://www.corporate-ir.net/media_files/priv/21180/WSAF/schedule/060601.htm

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on anticancer therapy. Genasense(TM), the Company's lead antisense compound, is currently in several Phase 3 clinical trials. Genta's product pipeline also comprises a portfolio of small molecules, including gallium-containing compounds for treatment of diseases associated with accelerated bone loss, and Androgenics compounds for prostate cancer. Genta aims to become a direct marketer of its pharmaceutical products in the United States. For more information about Genta, please visit our website at: http://www.genta.com.

The statements contained in this press release that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the expectations, beliefs, intentions or strategies regarding the future. Without limiting the foregoing, the words "anticipates," "believes," "expects," "intends," "may" and "plans" and similar expressions are intended to identify forward-looking statements. The Company intends that all forward-looking statements be subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect the Company's views as of the date they are made with respect to future events, but are subject to many risks and uncertainties, which could cause the actual results of the Company to differ materially from any future results expressed or implied by such forward- looking statements. For example, the results obtained in pre-clinical or clinical studies may not be indicative of results that will be obtained in future clinical trials, and lack of success or delays in the initiation or completion of clinical trials may occur as a result of many factors. Further examples of such risks and uncertainties also include, but are not limited to: the obtaining of sufficient financing to maintain the Company's planned operations timely development, receipt of necessary regulatory approvals, and acceptance of new products the successful application of the Company's technology to produce new products the obtaining of proprietary protection for any such technology and products the impact of competitive products and pricing and reimbursement policies and changing market conditions. The Company does not undertake to update forward-looking statements. Although the Company believes that the forward-looking statements contained herein are reasonable, it can give no assurances that the Company's expectations are correct. All forward looking statements are expressly qualified in their entirety by this cautionary statement and other factors detailed in the Company's reports filed with the Securities and Exchange Commission.

--------------------------------------------------------------------------------
Contact:
Tara Spiess, Investor Relations of Genta Incorporated,908-286-3980, [e-mail]; or Media - Brad Miles ext. 17, or Investors -Jonathan Fassberg ext. 16, both of BMC Communications-Trout Group,212-477-9007, for Genta Incorporated

http://www.clearstation.com/cgi-bin/bbs?post_id=2332293&Refer=http://www.clearstation.com/

Sara